Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Research output: Contribution to journal › Journal article › Research › peer-review

  • Kristoffer S Rohrberg
  • René K Olesen
  • Per Pfeiffer
  • Morten Ladekarl
  • Pappot, Helle
  • Ib J Christensen
  • Gunilla Høyer-Hansen
  • Morten Sørensen
  • Birgit G Skov
  • Ian Buysschaert
  • Peter Carmeliet
  • Lassen, Ulrik Niels
Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.
Original languageEnglish
JournalActa oncologica (Stockholm, Sweden)
Volume51
Issue number2
Pages (from-to)234-42
Number of pages9
DOIs
Publication statusPublished - Feb 2012

    Research areas

  • Adult, Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Carcinoma, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Prospective Studies, Quinazolines, Receptor, Epidermal Growth Factor, Survival Analysis, Treatment Outcome

ID: 107123908